Resilience Lab Enhances Mental Health Care Through Options MD Acquisition

New York-based mental health technology company Resilience Lab has acquired Options MD, an online platform for psychiatric medication management. This acquisition allows Resilience Lab to offer a more integrated approach to treating moderate to severe mental illnesses, combining psychotherapy with medication management. The addition of Options MD strengthens Resilience Lab’s ability to provide comprehensive care for patients suffering from conditions such as depression, anxiety, ADHD, and PTSD.

With the integration of Options MD, Resilience Lab will now offer AI-enabled diagnosis and treatment recommendations to its therapists, helping to improve the accuracy of mental health diagnoses and tailor care plans more effectively. Options MD's existing workforce will be retained, and the platform will continue to operate as a business unit under the Resilience Lab brand. This expansion reflects the company’s commitment to addressing more severe mental health conditions with a systematic and clinically proven approach.

This acquisition comes amid a broader trend of consolidation in the digital health sector, as companies seek to enhance their service offerings through mergers. Earlier this year, Resilience Lab raised $15 million in Series A funding, while Options MD secured $2.35 million in pre-seed funding. Other notable acquisitions include LetsGetChecked's purchase of Truepill and Health Catalyst’s acquisition of Lumeon, reflecting continued growth in the digital health space.